307 related articles for article (PubMed ID: 23460708)
1. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?
Domchek SM; Bradbury A; Garber JE; Offit K; Robson ME
J Clin Oncol; 2013 Apr; 31(10):1267-70. PubMed ID: 23460708
[No Abstract] [Full Text] [Related]
2. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
3. Testing for cancer susceptibility genes in children.
Laxova R
Adv Pediatr; 1999; 46():1-40. PubMed ID: 10645460
[TBL] [Abstract][Full Text] [Related]
4. Conversion technology and cancer predispositions.
Papadopoulos N
Methods Mol Biol; 2003; 223():415-23. PubMed ID: 12777743
[No Abstract] [Full Text] [Related]
5. The changing landscape of hereditary cancer genetic testing.
Webster RD; Ross JL; Arun BK
Cancer; 2018 Feb; 124(4):664-666. PubMed ID: 29266190
[No Abstract] [Full Text] [Related]
6. High penetrance of sequencing errors and interpretative shortcomings in mtDNA sequence analysis of LHON patients.
Bandelt HJ; Yao YG; Salas A; Kivisild T; Bravi CM
Biochem Biophys Res Commun; 2007 Jan; 352(2):283-91. PubMed ID: 17123466
[TBL] [Abstract][Full Text] [Related]
7. DNA testing for cancer predisposition.
Loescher LJ
Oncol Nurs Forum; 1998 Sep; 25(8):1317-27. PubMed ID: 9766286
[TBL] [Abstract][Full Text] [Related]
8. NHS pilots new genetic testing service for cancer patients.
Chinthapalli K
BMJ; 2013 May; 346():f3323. PubMed ID: 23693064
[No Abstract] [Full Text] [Related]
9. Need for clarification of data in a recent meta-analysis about TP53 codon 72 polymorphism and cancer susceptibility.
Lu PH; Wei MX; Li C; Shen W; Chen MB
Carcinogenesis; 2011 Mar; 32(3):443; author reply 444. PubMed ID: 21135152
[No Abstract] [Full Text] [Related]
10. Genetic testing for familial cancer. The French National Report (year 2003).
Eisinger F
Community Genet; 2008; 11(1):63-7. PubMed ID: 18196919
[TBL] [Abstract][Full Text] [Related]
11. "First do no harm" also applies to cancer susceptibility testing.
Burke W; Kahn MJ; Garber JE; Collins FS
Cancer J Sci Am; 1996; 2(5):250-2. PubMed ID: 9166540
[No Abstract] [Full Text] [Related]
12. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.
Papadopoulos N; Kinzler KW; Vogelstein B
Nat Biotechnol; 2006 Aug; 24(8):985-95. PubMed ID: 16900147
[TBL] [Abstract][Full Text] [Related]
13. Mouse models with modified p53 sequences to study cancer and ageing.
Clarke AR; Hollstein M
Cell Death Differ; 2003 Apr; 10(4):443-50. PubMed ID: 12719721
[TBL] [Abstract][Full Text] [Related]
14. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
Parhar P; Ezer R; Shao Y; Allen JC; Miller DC; Newcomb EW
Brain Res Mol Brain Res; 2005 Jun; 137(1-2):98-103. PubMed ID: 15950766
[TBL] [Abstract][Full Text] [Related]
15. Clinical selection of candidates for mutational testing for cancer susceptibility.
Lynch HT; Lynch PM
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 10):29-34. PubMed ID: 17354515
[TBL] [Abstract][Full Text] [Related]
16. [Molecular genetic tests in advanced non-small cell lung cancer: practical relevance].
Sebastian M; Niederle N; Thomas M; Reck M; Schmittel A; Fischer B; Overbeck T; Gröschel A; Deppermann M; Pirker R; Huber RM; Eberhardt W; Griesinger F
Dtsch Med Wochenschr; 2014 Oct; 139(41):2096-100. PubMed ID: 25268213
[No Abstract] [Full Text] [Related]
17. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?
Catts VS; Catts SV
Schizophr Res; 2000 Feb; 41(3):405-15. PubMed ID: 10728718
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and predictive value of criteria for p53 germline mutation screening.
Chompret A; Abel A; Stoppa-Lyonnet D; Brugiéres L; Pagés S; Feunteun J; Bonaïti-Pellié C
J Med Genet; 2001 Jan; 38(1):43-7. PubMed ID: 11332399
[No Abstract] [Full Text] [Related]
19. Diagnostic cancer genome sequencing and the contribution of germline variants.
Kilpivaara O; Aaltonen LA
Science; 2013 Mar; 339(6127):1559-62. PubMed ID: 23539595
[TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition testing for breast cancer.
Schulman JD; Stern HJ
Cancer J Sci Am; 1996; 2(5):244-9. PubMed ID: 9166539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
